Daily Ards Research Analysis
Three studies advance ARDS science from mechanism to translation: a mechanistic mouse–cell study links lactate-driven histone lactylation to endothelial ferroptosis and worse sepsis-induced lung injury; an organ-on-chip lung microphysiological system supports the pro-angiogenic therapeutic potential of primed cord blood MSCs; and a meta-analysis estimates a 14% incidence of post–liver transplant ALI/ARDS with notable heterogeneity by region and age.
Summary
Three studies advance ARDS science from mechanism to translation: a mechanistic mouse–cell study links lactate-driven histone lactylation to endothelial ferroptosis and worse sepsis-induced lung injury; an organ-on-chip lung microphysiological system supports the pro-angiogenic therapeutic potential of primed cord blood MSCs; and a meta-analysis estimates a 14% incidence of post–liver transplant ALI/ARDS with notable heterogeneity by region and age.
Research Themes
- Endothelial ferroptosis and epigenetic lactylation in sepsis-associated ARDS
- Organ-on-chip validation of mesenchymal stromal cell therapy for ARDS
- Incidence and risk stratification of ALI/ARDS after liver transplantation
Selected Articles
1. Histone lactylation exacerbates acute lung injury in septic mice by promoting ferroptosis in pulmonary microvascular endothelial cells.
In a septic mouse model and primary endothelial cells, elevated lactate drove H3K18 histone lactylation, upregulating ACSL4 and ferritinophagy (via GATA2→LC3/NCOA4), which induced endothelial ferroptosis and increased vascular permeability, worsening acute lung injury. Human S-ARDS data linked serum lactate and ferroptosis markers to poor prognosis, highlighting actionable epigenetic-ferroptotic targets.
Impact: This study identifies a mechanistic link between lactate, histone lactylation, and endothelial ferroptosis in sepsis-associated lung injury, bridging metabolism, epigenetics, and microvascular dysfunction. It provides concrete therapeutic targets (H3K18la, ACSL4, ferritinophagy) for future interventions.
Clinical Implications: Targets such as ACSL4, histone lactylation, and ferritinophagy could be leveraged with ferroptosis inhibitors or epigenetic modulators; lactate control may mitigate endothelial injury in sepsis-associated ARDS.
Key Findings
- Serum lactate peaked 18 h after CLP and promoted endothelial ferroptosis, increasing pulmonary vascular permeability and aggravating ALI.
- Lactate increased H3K18 histone lactylation, driving ACSL4 transcription and lipid peroxidation in MPMVECs.
- H3K18la also enhanced LC3 transcription and, via GATA2, upregulated NCOA4 to facilitate ferritinophagy.
- In S-ARDS patients, serum lactate correlated with ferroptosis levels and poor prognosis.
Methodological Strengths
- Multi-system validation across in vivo septic mouse model, primary endothelial cells, and transcriptomics
- Mechanistic dissection linking epigenetic mark (H3K18la) to ferroptosis pathways (ACSL4, ferritinophagy)
Limitations
- Preclinical model; translational relevance requires validation in human tissues and interventional studies
- Human data are correlational; sample sizes and reproducibility across centers not reported
Future Directions: Test ferroptosis inhibitors or epigenetic modulators targeting H3K18la/ACSL4/ferritinophagy in sepsis-ALI models, and validate biomarkers in prospective S-ARDS cohorts.
BACKGROUND: Circulating lactate is associated with poor prognosis in sepsis-induced acute lung injury (S-ALI). However, it remains unclear whether microvascular dysfunction, a hallmark of S-ALI, is related to circulating lactate levels and what the underlying mechanisms are. The aim of this study was to investigate the role and mechanisms of lactate in pulmonary microvascular dysfunction in S-ALI. METHODS: The effects of lactate on pulmonary microvascular function were assessed in a septic mouse model. Primary mouse pulmonary microvascular endothelial cells (MPMVECs) were isolated to evaluate the impact of lactate on MPMVEC permeability. Transcriptomic sequencing was employed to investigate the involvement of lactate in regulating MPMVEC ferroptosis, and the results were validated by RESULTS: The mouse serum lactate level reached a peak at 18 h after caecal ligation and puncture surgery. Elevated lactate levels during sepsis promoted ferroptosis in PMVECs, leading to increased pulmonary vascular permeability and exacerbation of ALI. Mechanistically, lactate increased the lactylation of histone H3 at K18 (H3K18la), which promoted ACSL4 transcription in MPMVECs, resulting in excessive lipid peroxidation. Additionally, elevated H3K18la promoted LC3 transcription and indirectly upregulated NCOA4 expression through the transcription factor GATA2, facilitating ferritinophagy. Serum lactate levels were significantly correlated with ferroptosis levels in S-ARDS patients, and both were associated with poor patient prognosis. CONCLUSIONS: This study revealed a critical role for high lactate-derived histone lactylation in PMVEC ferroptosis and the progression of ALI during sepsis, providing new insights and potential therapeutic mechanisms.
2. Lung Microphysiological System Validates Novel Cell Therapy for Acute Respiratory Distress Syndrome.
Using an LPS-injured lung microphysiological system, primed hUCB-MSCs enhanced angiogenesis programs and tip-like endothelial cell states, outperforming dexamethasone on pro-angiogenic signatures by single-cell RNA-seq and fluorescence imaging. Findings support development of MSC-based therapeutics as an alternative to corticosteroids for ARDS.
Impact: Introduces a lung organ-on-chip platform integrating scRNA-seq to functionally benchmark a primed MSC product against standard therapy, offering translational insights without immediate in vivo risks.
Clinical Implications: Supports advancing hUCB-MSCs to preclinical animal testing and early-phase trials in ARDS; pro-angiogenic effects suggest dosing and timing strategies to restore endothelial integrity.
Key Findings
- Developed an LPS-injured lung microphysiological system modeling ARDS.
- Primed hUCB-MSCs activated endothelial angiogenesis pathways and increased tip-like endothelial cells.
- Fluorescence imaging corroborated scRNA-seq findings, supporting therapeutic potential versus dexamethasone.
Methodological Strengths
- Organ-on-chip platform with disease-relevant stimulus (LPS) and advanced readouts (scRNA-seq, fluorescence imaging)
- Direct comparison to standard therapy (dexamethasone)
Limitations
- In vitro platform; lacks systemic immune and multi-organ interactions
- No in vivo efficacy or safety data; sample size and manufacturing variability not detailed
Future Directions: Evaluate hUCB-MSCs in relevant animal ARDS models, define dose/timing, and identify predictive biomarkers of response using the MPS-to-clinic pipeline.
Acute Respiratory Distress Syndrome (ARDS) is a life-threatening condition characterized by severe inflammation and lung damage, leading to critical hypoxemia. Despite its high mortality rate, the only currently available treatment, Dexamethasone, is associated with significant side effects. This study aims to evaluate the efficacy of primed human umbilical cord blood-derived mesenchymal stem cells (hUCB-pMSCs) as a potential alternative treatment for ARDS. A novel lung microphysiological system (MPS) modeling the lung environment is developed and treated with lipopolysaccharide (LPS) to simulate ARDS. The effects of hUCB-pMSCs and dexamethasone are compared using state-of-the-art methods, including fluorescence-based imaging and single-cell RNA sequencing. The hUCB-pMSCs significantly activated angiogenesis-related pathways in endothelial cells and enhanced the formation of tip-like endothelial cells involved in new blood vessel formation. These findings are corroborated by fluorescence microscopy, demonstrating the robust potential of hUCB-pMSCs as a therapeutic approach. Overall, the results support the potential of hUCB-pMSCs as a promising alternative treatment for ARDS.
3. The incidence and risk factors of acute lung injury after liver transplantation: A systematic review and meta-analysis.
Across 11 studies (n=10,007), the pooled incidence of ALI after liver transplantation was 14% with extreme heterogeneity (I2=97%). Rates were higher in Asian and pediatric cohorts; retrospective designs reported lower incidence, and publication bias was present.
Impact: Provides the most comprehensive synthesis to date of ALI/ARDS burden after liver transplantation, highlighting high-risk subgroups and methodological gaps.
Clinical Implications: Supports targeted perioperative monitoring and prevention strategies in pediatric and Asian populations; underscores the need for standardized definitions and prospective data collection.
Key Findings
- Pooled ALI incidence after liver transplantation was 14% (95% CI 6–25%) across 10,007 patients.
- Marked heterogeneity (I2=97%) with higher incidence in Asian studies and pediatric cohorts.
- Retrospective studies reported lower incidence than prospective ones; publication bias was confirmed.
Methodological Strengths
- Comprehensive search with quality assessment (Newcastle-Ottawa scale) and subgroup analyses
- Assessment of heterogeneity and publication bias (I2, funnel plots, Egger's test)
Limitations
- Extremely high heterogeneity limits precision and generalizability
- Potential inconsistencies in ALI/ARDS definitions and perioperative practices across studies
Future Directions: Prospective, standardized multicenter cohorts with harmonized ALI/ARDS definitions to refine incidence estimates and risk models; evaluate preventive bundles.
BACKGROUND: End-stage liver disease is associated with significant global morbidity, with liver transplantation being the only curative treatment option. Posttransplant acute lung injury (ALI) and acute respiratory distress syndrome can adversely affect outcomes. This study aimed to evaluate the incidence of ALI following liver transplantation and to identify associated risk factors. METHODS: A comprehensive literature search was conducted up to February 24, 2024, across databases such as PubMed, EMBASE, Cochrane Controlled Register of Trials, and Web of Science. Studies were included if they reported the incidence of ALI in liver transplant patients. The quality of the studies was assessed using the Newcastle-Ottawa scale. Data analysis utilized fixed-effects and random-effects models based on heterogeneity, and subgroup analyses investigated the impact of age, region, and study design on ALI incidence. Publication bias was evaluated through funnel plots and Egger's test. RESULTS: The meta-analysis comprised 11 studies from 2000 to 2023, assessing 10,007 liver transplant patients, among whom 198 cases of ALI were reported. Incidence rates varied significantly from 0.1% to 44.6%. The pooled incidence rate was 0.14 (95% confidence interval: 0.06; 0.25), indicative of high heterogeneity (I2 = 97%). Subgroup analyses revealed higher incidence rates in Asian studies and pediatric populations, while retrospective studies reported a lower incidence compared to prospective ones. Publication bias was confirmed. CONCLUSION: The study found a 14% incidence of lung injury post-liver transplantation, with variation by age and region, underscoring the need for personalized perioperative care and targeted monitoring for high-risk patients.